EUVIMEDEUVIMED entdecken
Crossref

Assessment of the 2022 Constitutional Mismatch Repair Deficiency Syndrome Diagnostic Criteria Using the International Replication Repair Deficiency Consortium

Melyssa Aronson iD, Lucie Stengs, Melissa Edwards, Jadyn Moussadji, Vanessa Bianchi, Jiil Chung, Logine Negm iD, Nicole K Gygi, Daniel C Bowers iD, Bryson W Katona iD, Yosef Maruvka, Miriam Bornhorst iD und 4 weitere

JCO Precision Oncology · 2026-11 · 10 (11)

DOI: 10.1200/po-26-00979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-11. Verfasst von Melyssa Aronson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada. Hauptthemen laut MEDLINE: DNA Mismatch Repair, Neoplastic Syndromes, Hereditary, Brain Neoplasms, Colorectal Neoplasms. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Constitutional mismatch repair deficiency syndrome (CMMRD) syndrome, caused by inherited biallelic mismatch repair (MMR) gene loss, is characterized by early-onset cancers and neurofibromatosis Type 1 (NF1) features. Genetic heterogeneity of syndromes with replication repair deficiency (RRD) and non-RRD conditions (eg, Lynch syndrome (LS) and NF1, respectively) leads to diagnostic challenges. Seven diagnostic criteria (CMMRD1-CMMRD7) were established in 2022 incorporating germline results, ancillary tests, and clinical manifestation. This study reviews the use of these criteria in identifying CMMRD.

Methods

Individuals suspected of CMMRD referred to the International Replication Repair Deficiency Consortium in Toronto, Canada, had clinical manifestation, family history, germline, MMR immunohistochemistry (IHC) of non-neoplastic (NN-IHC) and tumor tissue, and LOGIC obtained to assess the diagnostic criteria.

Results

A total of 580 individuals were identified, with 159 excluded because of insufficient information resulting in 421 individuals assessed using the diagnostic criteria. Of these, 358 (85%) were classified as CMMRD/suspected CMMRD (n = 270), LS/likely LS (n = 78), or other hereditary conditions (n = 10). Sixty-three individuals could not be classified because of the lack of or discordant results. Of the 270 patients with CMMRD syndrome, 241 met the published criteria and 29 were suspected of CMMRD on the basis of fulfilling criteria with a discordant functional result or suspicious genotype/phenotype. CMMRD1-CMMRD7 criteria were all identified, with 57% (n = 137) fulfilling CMMRD1 criteria. Early-onset gliomas and GI cancers occurred in LS, POLE , TP53 , and NF1. Digenic LS and concurrent hereditary cancer syndromes were identified.

Conclusion

The 2022 CMMRD syndrome diagnostic criteria provided a useful framework for establishing CMMRD syndrome and distinguishing it from similar conditions. A clinically meaningful subset remained difficult to classify despite suspicion of CMMRD. Refinement of CMMRD syndrome diagnostic criteria may address atypical presentation and discordant functional results. Limitations include incomplete availability of germline/functional testing, discordant/inconclusive results, and inherent referral bias to a specialized RRD consortium.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Mismatch RepairNeoplastic Syndromes, HereditaryBrain NeoplasmsColorectal NeoplasmsHumansFemale

Autor:innen und Institutionen

  • Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.
  • Zane Cohen Centre, Mount Sinai Hospital, Toronto, ON, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Brian D. Jellison Cancer Institute, Sarasota Memorial Health Care System, Sarasota, FL.
  • Division of Pediatric Hematology-Oncology, Department of Pediatrics, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical School, Dallas, TX.
  • Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

ORCID-Profile: Melyssa Aronson, Logine Negm, Daniel C Bowers, Bryson W Katona, Miriam Bornhorst, Cynthia Hawkins, Uri Tabori, Anirban Das

Zitieren

APA

Aronson, M., Stengs, L., Edwards, M., Moussadji, J., Bianchi, V., Chung, J., Negm, L., Gygi, N. K., Bowers, D. C., Katona, B. W., Maruvka, Y., Bornhorst, M., Jacobsen, N., Hawkins, C., Tabori, U., & Das, A. (2026). Assessment of the 2022 Constitutional Mismatch Repair Deficiency Syndrome Diagnostic Criteria Using the International Replication Repair Deficiency Consortium. JCO Precision Oncology, 10(11). https://doi.org/10.1200/po-26-00979

Vancouver

Aronson M, Stengs L, Edwards M, Moussadji J, Bianchi V, Chung J, et al. Assessment of the 2022 Constitutional Mismatch Repair Deficiency Syndrome Diagnostic Criteria Using the International Replication Repair Deficiency Consortium. JCO Precision Oncology. 2026;10(11). doi:10.1200/po-26-00979

BibTeX
@article{Aronson2026,
  author = {Aronson, Melyssa and Stengs, Lucie and Edwards, Melissa and Moussadji, Jadyn and Bianchi, Vanessa and Chung, Jiil and Negm, Logine and Gygi, Nicole K and Bowers, Daniel C and Katona, Bryson W and Maruvka, Yosef and Bornhorst, Miriam and Jacobsen, Noah and Hawkins, Cynthia and Tabori, Uri and Das, Anirban},
  title = {Assessment of the 2022 Constitutional Mismatch Repair Deficiency Syndrome Diagnostic Criteria Using the International Replication Repair Deficiency Consortium},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {11},
  doi = {10.1200/po-26-00979}
}
Kostenlos starten →